The global Radiopharmaceutical Theranostics Market is expected to experience significant expansion over the next decade as healthcare providers increasingly embrace precision medicine strategies that combine advanced imaging with targeted therapeutic interventions. “According to a recent study by SNS Insider, the global Radiopharmaceutical Theranostics Market size valued at USD 2.42 billion in 2025, is anticipated to grow to USD 6.93 billion by 2035, registering a CAGR of 11.14% over the 2026–2035 forecast period.”
The rise in the need for individualized cancer therapies, investment in state-of-the-art nuclear medicine facilities, and continuous developments in the field of radiopharmaceutical therapy are bringing about a paradigm shift in the future landscape of cancer treatments. Innovative treatment systems which allow improved diagnosis and precise treatment of cancers are being adopted by healthcare facilities.
Individualized cancer therapies becoming common practice means that radiopharmaceutical theranostics will have more importance in oncology treatment programs.
To Get Detailed Insights on the Radiopharmaceutical Theranostics Market – Request a Sample Report
Precision Medicine Continues to Transform Oncology Care
The healthcare sector around the world is putting in enormous investments in technologies that facilitate clinical decision-making by delivering therapies in an extremely precise manner. Developments in molecular imaging, radiopharmaceuticals, and personalized therapy planning have led to the emergence of novel possibilities in many types of cancers.
Collaborations between pharma companies, research institutes, healthcare organizations, and experts in the field of nuclear medicine are driving innovation in the sector. The expansion in the production capacity of radiopharmaceuticals and the strengthening of the supply chain logistics network have also been contributing factors towards this objective.
Continued scientific progress is expected to strengthen the role of radiopharmaceutical therapies within comprehensive cancer treatment strategies over the coming decade.
Key Market Findings Highlight Growth Opportunities
Among product categories, theranostic pairs accounted for 62% of global market revenue in 2025, reflecting increasing adoption of integrated diagnostic and therapeutic approaches that support personalized patient management.
Meanwhile, therapeutic radiopharmaceuticals are projected to register the fastest growth through 2035, driven by expanding clinical applications and increasing investment in targeted oncology therapies.
By radioisotope, Lutetium-177 (Lu-177) represented 56% of total market revenue in 2025, maintaining its leadership through broad clinical utilization and established treatment protocols. At the same time, Actinium-225 is expected to emerge as the fastest-growing radioisotope segment, supported by growing interest in next-generation targeted alpha therapies for difficult-to-treat cancers.
Application trends continue to demonstrate strong momentum. Oncology accounted for 82% of market revenue in 2025, underscoring the central role of theranostic technologies in modern cancer care. Meanwhile, neurology is anticipated to witness the fastest growth during the forecast period, reflecting increasing research into molecular imaging and targeted therapeutic applications for neurological disorders.
Among end users, hospitals accounted for 59% of global market revenue in 2025, supported by established nuclear medicine infrastructure and multidisciplinary clinical expertise. Specialty cancer centers are expected to record the fastest expansion through 2035 as healthcare providers continue investing in dedicated precision oncology programs.
Expanding Oncology Infrastructure Supports Market Development
The healthcare providers have been enhancing their abilities for treating cancer patients by building nuclear medicine departments, employing latest imaging techniques, and offering oncology services. The growth of treatment centers makes it easier for patients to get treatment as well as use the most advanced methods of treatment.
Manufacturers are concentrating on increasing production of the equipment, availability of the isotopes, and development of new platforms for treatment. These activities will play an important role in the market growth in the future.
Regional Markets Continue to Strengthen
North America comprised a market share of 42.30% in 2025, owing to the presence of efficient healthcare facilities, favorable regulations, well-established nuclear medicine programs, and growing investments in precision oncology technology. North America still remains one of the key centers for clinical innovations and advanced radiopharmaceutical therapies.
Meanwhile, Asia Pacific will be considered as the highest growing regional market with an estimated CAGR of around 19.1% from 2022 to 2035. The increase in health care infrastructure, cancer treatment facilities, advanced diagnostic installations, and development in radiopharmaceuticals in the region are generating significant growth opportunities in many countries of Asia Pacific.
Industry Leaders Continue to Advance Innovation
Competition within the radiopharmaceutical theranostics market remains dynamic as leading healthcare companies continue investing in product innovation, manufacturing expansion, strategic collaborations, and clinical development programs aimed at expanding precision oncology capabilities worldwide.
Key companies operating in the global radiopharmaceutical theranostics market include
- Novartis
- Bayer
- GE HealthCare
- Bracco Imaging
- Curium Pharma
- Lantheus Holdings
- Telix Pharmaceuticals
- Eckert & Ziegler
- Cardinal Health
- Siemens Healthineers
An SNS Insider analyst Parry Kardani commented, "The convergence of molecular imaging, targeted radiopharmaceutical therapies, and precision oncology is redefining cancer treatment worldwide. Continued investment in innovative radioisotopes, manufacturing capacity, and specialized treatment infrastructure is expected to create substantial opportunities across the radiopharmaceutical theranostics market over the next decade."
About the Author
Get in touch
